Drug Profile
Esomeprazole strontium - Hanmi Pharmaceutical
Alternative Names: DR esomeprazole; Esomeprazole strontium delayed-release; Esomeprazole strontium tetrahydrate; Esomezol; HIP1601Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antibacterials; Antiulcers; Gastric antisecretories; Small molecules
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Duodenal ulcer; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; NSAID-induced ulcer; Zollinger-Ellison syndrome
Most Recent Events
- 26 Nov 2020 Hanmi Pharmaceutical completes a phase III trial in Gastro-oesophageal-reflux (Combination therapy) in South Korea (NCT04080726)
- 20 Feb 2020 Hanmi Pharmaceutical completes a phase I trial in esomeprazole strontium (In volunteers) in South Korea (PO) (NCT04204629)
- 13 Jan 2020 Hanmi Pharmaceutical initiates a phase I trial for esomeprazole strontium (In volunteers) in South Korea (PO) (NCT04204629)